NOX4 and neoplasm: Pharmacological NOX4 inhibition (GKT137831) disrupts this axis—reducing CAFs’ contractility and MDSC infiltration—which synergizes with anti-PD1 therapy to reverse T cell exclusion and improve tumor regression [44].